Mesa Laboratories (MLAB)
NASDAQ:MLAB
Want to see MLAB full AI Analyst Report?
Top Page
Mesa Laboratories
(NASDAQ:MLAB)
Select Model
Select Model
Rating:65Neutral
Price Target:
$111.00
▲(7.70% Upside)
Action:ReiteratedDate:04/18/26
The score is driven primarily by improving fundamentals with strong and consistent free cash flow and better leverage, offset by continued earnings volatility and weak returns. Technicals are supportive with a clear uptrend, though momentum indicators are near overbought. Valuation is a headwind given the ~29.9 P/E and low dividend yield, and the CEO transition adds modest uncertainty despite generally positive framing.
Positive Factors
Free Cash Flow Strength
Consistent multi-year free cash flow (~$37.7M TTM) yields durable internal funding for reinvestment, debt reduction, and opportunistic capital allocation. Strong cash conversion cushions volatile net income, increasing financial flexibility and supporting strategic initiatives over the medium term.
Negative Factors
Earnings Volatility
The company’s net results have swung materially — including a severe FY2024 loss and recent annual losses — reducing predictability for earnings and cash available for returns. Persistent volatility complicates planning, capital allocation and investor confidence over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Consistent multi-year free cash flow (~$37.7M TTM) yields durable internal funding for reinvestment, debt reduction, and opportunistic capital allocation. Strong cash conversion cushions volatile net income, increasing financial flexibility and supporting strategic initiatives over the medium term.
Read all positive factors
Mesa Laboratories (MLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$552.48M
Dividend Yield0.79%
Average Volume (3M)148.03K
Price to Earnings (P/E)29.9
Beta (1Y)1.41
Revenue Growth4.12%
EPS GrowthN/A
CountryUS
Employees736
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)3.07
Shares Outstanding5,524,813
10 Day Avg. Volume101,777
30 Day Avg. Volume148,032
Financial Highlights & Ratios
PEG Ratio3.29
Price to Book (P/B)4.03
Price to Sales (P/S)2.67
P/FCF Ratio15.23
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda13.61
Forecast
1Y Price Target
$104.50Price Target Upside1.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)8.52
Revenue Forecast (FY)$263.03M
Mesa Laboratories Business Overview & Revenue Model
Company Description
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segme...
How the Company Makes Money
Mesa Laboratories makes money primarily by selling products and solutions that support customers’ ongoing compliance, validation, and monitoring needs. Its revenue is generated through multiple product lines, including: (1) Sterilization and Disin...
Mesa Laboratories Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
55
Neutral
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 247.54M | 240.98M | 216.19M | 219.08M | 184.34M | 133.94M |
| Gross Profit | 150.03M | 150.87M | 133.25M | 133.69M | 109.09M | 87.01M |
| EBITDA | 44.33M | 42.35M | -238.38M | 37.52M | 32.53M | 27.99M |
| Net Income | 3.73M | -1.97M | -254.25M | 930.00K | 1.87M | 3.27M |
Balance Sheet | ||||||
| Total Assets | 434.85M | 433.35M | 446.80M | 661.83M | 707.37M | 601.48M |
| Cash, Cash Equivalents and Short-Term Investments | 28.98M | 27.32M | 28.21M | 32.91M | 49.35M | 263.87M |
| Total Debt | 103.41M | 181.47M | 231.30M | 186.14M | 221.13M | 146.70M |
| Total Liabilities | 248.16M | 273.52M | 301.40M | 268.35M | 313.57M | 195.25M |
| Stockholders Equity | 186.69M | 159.83M | 145.39M | 393.48M | 393.80M | 406.23M |
Cash Flow | ||||||
| Free Cash Flow | 37.69M | 42.31M | 41.57M | 23.44M | 34.79M | 35.08M |
| Operating Cash Flow | 41.53M | 46.81M | 44.13M | 27.98M | 39.22M | 37.07M |
| Investing Cash Flow | -3.84M | -4.50M | -81.31M | -9.49M | -305.23M | -1.99M |
| Financing Cash Flow | -42.29M | -44.51M | 32.84M | -33.33M | 52.58M | 146.23M |
Mesa Laboratories Technical Analysis
Positive
103.06
Price Trends
89.30
Positive
85.20
Positive
78.69
Positive
Market Momentum
4.03
Negative
72.65
Negative
87.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Positive. The current price of 103.06 is above the 20-day moving average (MA) of 90.65, above the 50-day MA of 89.30, and above the 200-day MA of 78.69, indicating a bullish trend. The MACD of 4.03 indicates Negative momentum. The RSI at 72.65 is Negative, neither overbought nor oversold. The STOCH value of 87.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLAB.
Mesa Laboratories Risk Analysis
Mesa Laboratories disclosed 47 risk factors in its most recent earnings report. Mesa Laboratories reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mesa Laboratories Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $756.85M | 70.12 | 8.90% | 1.07% | 11.42% | 5.37% | |
66 Neutral | $949.54M | 93.63 | 9.64% | ― | 0.36% | 1138.56% | |
65 Neutral | $552.48M | 29.91 | 2.14% | 0.79% | 4.12% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | $206.69M | 42.82 | 2.37% | 2.25% | 4.82% | ― | |
58 Neutral | $739.25M | -13.49 | -70.17% | ― | 64.15% | -119.81% | |
57 Neutral | $803.43M | 96.46 | 1.59% | ― | 0.22% | -46.18% |
* Technology Sector Average
MLAB
Mesa Laboratories
103.31
-14.85
-12.57%
DAKT
Daktronics
19.70
6.28
46.80%
LPTH
Lightpath Technologies
13.70
11.21
450.20%
LYTS
Lsi Industries
23.89
8.10
51.34%
RELL
Richardson Electronics
14.48
5.77
66.17%
VPG
Vishay Precision Group
60.22
33.94
129.15%
Mesa Laboratories Corporate Events
Executive/Board Changes
Mesa Laboratories CEO Gary Owens Announces Planned Departure
Neutral
Mar 23, 2026
Mesa Laboratories, Inc. announced on March 9, 2026, that President and Chief Executive Officer Gary Owens will depart the company effective on or about April 13, 2026, and subsequently entered into a Transition Agreement on March 20, 2026, under w...
Business Operations and StrategyExecutive/Board Changes
Mesa Laboratories Names New CEO for Next Phase
Positive
Mar 9, 2026
On March 9, 2026, Mesa Laboratories announced that long‑time President and CEO Gary Owens, who has led the company since 2017 through significant growth and market expansion, will step down on April 12, 2026. The board emphasized that his de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.